Lv5
1570 积分 2021-03-16 加入
P3.12.57 Phase I/II Study of FHND9041 in T790M-Positive Advanced NSCLC Patients Progressed After Prior EGFR-TKI Therapy
2个月前
已关闭
Abstract CT232: Safety, efficacy, and tolerability of FHND9041 capsules as first-line treatment in patients with EGFR sensitive mutations or second/third-line treatment in patients with T790M+ advanced non-small cell lung cancer (NSCLC): results from a phase I/II single-arm, multi-center, open-label study
2个月前
已关闭
Comprehensive first-in-human phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancer
2个月前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
2个月前
已完结
Circulating tumor cells with increasing aneuploidy predict inferior prognosis and therapeutic resistance in small cell lung cancer
3个月前
已完结
Abstract 6390: Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer
3个月前
已完结
ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?
3个月前
已完结
MA11.08 Longitudinal Circulating Tumor DNA Dynamics Predict Therapeutic Efficacy in ES-SCLC Treated With Immunotherapy
3个月前
已关闭
An ultrasensitive method for detection of cell-free RNA
3个月前
已完结
Disease Course and Treatment Outcomes in Patients With De Novo Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Insertion: Two Case Reports
3个月前
已完结
皖公网安备34019202002308
